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Abstract: Since the first endocannabinoid anandamide was identified in 1992, extensive 
research has been conducted to characterize the elements of the tightly controlled 
endocannabinoid signaling system. While it was established that the activity of 
endocannabinoids are terminated by a two-step process that includes cellular uptake and 
degradation, there is still a continuing debate about the mechanistic role of these processes 
in inactivating anandamide signals. 
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1. Introduction  
The medical use of Cannabis sativa L. is as ancient as the two thousand years old Chinese treatise 
that described the use of the female plant as an anesthetic in surgery by using its resin mixed with wine 
[1]. The term “cannabinoids” covers a wide range of compounds derived from the Cannabis plant. The 
first attempt to identify a cannabinoid was reported by Wood et al., who isolated cannabinol (CBN) 
from a red oily extract of Cannabis [2], while 60 years later, the structures of the cannabidiol (CBD) 
and the psychoactive compound ()-trans-∆9-tetrahydrocannabinol (∆9-THC) were reported by 
Mechoulam’s laboratory [3]. To date, there are over 65 cannabinoids with various medical applications 
including treatment of multiple sclerosis and obesity, pain relief and cancer chemotherapy [4-7].  
The identification of cannabinoid CB1 [8, 9] and CB2 receptors [10] was the trigger for rapid 
identification of their natural endogenous ligands known as endocannabinoids. These are lipid inter-
cellular signaling molecules derived from arachidonic acid conjugated with glycerol or ethanolamine 
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and include anandamide, also known as N-arachidonylethanolamine (anandamide, AEA) [11] and 2-
arachidonoylglycerol (2-AG) [12]. More recently-discovered endogenous cannabinoids include 
noladin ether (2-arachidonoylglycerolether) [13], N-arachidonoyl-dopamine (NADA) [14] and 
virodhamine [15] (Figure 1) although AEA and 2-AG are the only detectable endocannabinoids so far 
in human plasma using LCMS analysis [16]. 
Figure 1. Chemical structures of proposed endocannabinoids. 
 
 
 
 
 
 
 
 
 
 
 
 
The present review gives a general view of the endocannabinoid system and focuses on the 
inactivation of anandamide signaling processes in the light of extensive research that has been aimed at 
addressing many of the questions regarding the anandamide reuptake and degradation processes as 
effective mechanisms for terminating endocannabinoid actions. 
2. Endocannabinoid System 
The endocannabinoid system is a lipid signaling system which has important regulatory functions 
throughout the body in all vertebrates. It consists of endocannabinoid ligands along with their 
receptors, signaling pathways and cellular machinery for their biosynthesis [17], uptake [18] and 
degradation [19]. The present review will focus on AEA as its pharmacological activities and 
metabolism has been more extensively investigated compared with other recently discovered and 
emerging endocannabinoids. 
Furthermore, three fatty acid-derived compounds were found to function in concert with 
endocannabinoids despite having no affinity for cannabinoid receptors and, thus, known as 
endocannabinoid congeners. These compounds are: (A) N-palmitoylethanolamine (PEA), a well 
known anti-inflammatory compound which was found in lipid extracts of various natural products. It 
was shown to enhance the endocannabinoid actions on cannabinoid receptors by interfering with their 
inactivation [20]; (B) oleamide, a primary fatty acid amide that is accumulated in the cerebrospinal 
fluid (CSF) of sleep–deprived cats, was found to be degraded by fatty acid amide hydrolase (FAAH). 
Its systemic administration produced cannabimimetic effects [21]; (C) N-arachidonoyl amino acids, 
formed by conjugation of arachidonic acid with various amino acids including, glycine, alanine, valine, 
cysteine and serine [22]. These compounds act as endogenous modifiers of endocannabinoid activities 
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through indirect entourage effects on endocannabinoid degradation and/or reuptake [23]. However, the 
effects of these compounds in vivo remain to be determined.  
Figure 2. Enzymes involved in AEA synthesis; N-acyltransferase (NAT), protein tyrosine 
phosphatase (PLP) and phospholipase D (PLD) and in AEA degradation; fatty acid amide 
hydrolase (FAAH), cyclooxygenase-2 (COX-2), cytochrome P450, and 12-, 15-lipo-
oxygenase (LOX). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
2.1. Synthesis and release 
Anandamide is synthesized (Figure 2) by stimulus-dependent cleavage of its precursor, N-
arachidonoyl-phosphatidylethanolamine (NArPE). NArPE is formed by the enzyme N-acyltransferase 
(NAT) in the presence of calcium. Cyclic AMP was found to enhance the activity of NAT through 
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activating protein kinase A [24]. AEA is released from NArPE by cleavage of phosphodiester bond 
catalyzed by a phospholipase D (PLD), a member of metallo-β-lactamase family [25]. Other 
alternative pathways for AEA synthesis have been also reported [26-28]. 
Many factors contribute to anandamide release from the plasma membrane. Neuronal activity (i.e., 
depolarization) produces Ca2+-dependent anandamide release. The anandamide then diffuses laterally 
in the cell membrane to exert its effects on targeted receptors and/or ion channels [29]. Alternatively, 
anandamide could be released into the extracellular fluid and subsequently bind to protein carrier as 
albumin to reach a distant targets at presynaptic terminals [30]. 
2.2. Functions and actions 
In order to characterize the exact meaning of the term “inactivation”, we should outline briefly the 
functions and actions of endocannabinoid system. The tissue distribution of different types of 
cannabinoid receptor accounts for the diversity of endocannabinoid effects either centrally or 
peripherally.  Extensive studies had been conducted to address the possible physiological functions of 
the endocannabinoid system. Generally speaking, endocannabinoids are produced on demand and act 
as local mediators that control the function of the secretory cells i.e., autocrine, or the adjacent cells 
i.e., paracrine [31]. These actions vary according to the targeted receptor. Thus, CB1 receptors mediate 
the neuromodulatory action regulating pain perception and food intake [5,32], as well as, 
cardiovascular, respiratory and gastrointestinal effects [33-35], while CB2 receptors mediate the 
humoral immune modulation [36]. 
Cannabinoid receptor signaling is mainly coupled to Gi/o proteins with consequent inhibition of 
adenylyl cyclase and PKA along with stimulation of mitogen-activated protein kinase (MAPK) that 
regulates nuclear transcription factors [37,38]. These effects are probably mediated by the free β/γ G-
protein subunit dimers although there remains some uncertainty about the subtype of Gi/o proteins that 
might be associated with the responses [39]. It is thought that the same mechanism is responsible for 
activation of phosphoinositide-3-kinase (PI-3-K). Active PI-3-K phosphorylate the inositol lipids and 
with subsequent activation of Raf-1 protein kinase [40]. Activation of CB2 receptors modulates the 
cytokine production and the migration of the immune cells thus influencing the immune response [41]. 
Anandamide has been found to inhibit high voltage-activated calcium currents but at least part of 
this effect is insensitive to CB1 receptor inhibition suggesting multiple mechanisms of high voltage-
activated calcium currents (VACC) modulation [42, 43]. Apart from activation of cannabinoid 
receptors, anandamide was found to produce direct inhibition of Shaker-related Kv1.2 channels, an 
action that was insensitive to either pertussis toxin or CB1 cannabinoid receptor antagonist, SR141716 
[44]. Additionally, anandamide was reported to inhibit the delayed rectifier component of the 
potassium current in smooth muscle preparation from rat aorta in a cannabinoid receptor-independent 
way [45].  
3. Reuptake 
Anandamide movement across the cell membrane is still a matter of considerable debate being 
either mediated through the concentration gradient (i.e., simple diffusion) or through specific 
transporter machinery (i.e., facilitated diffusion). Being lipophilic in nature, anandamide rapidly 
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accumulates inside the cell through a temperature-sensitive, ATP-independent, saturable mechanism 
that could be inhibited by several analogues [46-49]. There are also pieces of evidence that suggest the 
presence of a carrier protein, anandamide membrane transporter (AMT) that bind and translocates 
anandamide in both directions across the cell membrane. These findings were confirmed by the 
systemic administration of LY2318912, a competitive inhibitor of anandamide uptake, which elevates 
anandamide level 5-fold in the brain [50]. On the other hand, there is also much evidence to suggest 
that anandamide movement across the cell occurs by simple diffusion along the concentration gradient 
enhanced by rapid intracellular hydrolysis of anandamide catalyzed by (FAAH). This hydrolysis 
mechanism could be responsible for the apparent saturability of anandamide transport [51-53]. These 
suggestions were enforced by finding that the inhibiting effects of LY2318912 on AEA reuptake were 
mediated through FAAH inhibition that in turn reduces the concentration gradients necessary for AEA 
movement across the cell membrane [54,55]. Moreover, temperature was found to affect to a greater 
extent the concentration of free anandamide rather than affecting the reuptake process itself [56]. It 
was also found that the intracellular concentration of anandamide is 1,000-fold its concentration in the 
extracellular compartment at equilibrium in the cerebellar granule neurons [57]. This could be 
explained by the intracellular reversible sequestration of anandamide via its association with either 
membranous compartments (e.g. endoplasmic reticulum) [58] or an intracellular protein [59] leaving 
only a small fraction of free anandamide. This sequestration could explain apparent saturation of 
putative transport processes and selective inhibition of anandamide accumulation by related lipophilic 
molecules [60]. Additionally, the AEA uptake inhibitor, AM404, was thought to provide evidence for 
the existence of AMT [18]. Later on, it was demonstrated that AM404 is not selective for uptake 
inhibition but interferes with anandamide hydrolysis by acting as a substrate for FAAH [61].  
Parallel to the debate about the existence of AMT, there is another debate about the role of AEA 
uptake in terminating AEA activity. The endocannabinoid anandamide was found to activate transient 
receptor potential vanilloide receptor type 1 (TRPV1) on the perivascular sensory nerves an activity 
that subsequently produced vasodilatation of associated vascular smooth muscle [62]. Furthermore, it 
was demonstrated that AEA acts as a full agonist for TRPV1 receptors in recombinant expression 
systems. Anandamide also shows low affinity for TRPV1 receptors but this could be enhanced by 
palmitoylethanolamide [63]. In cultured DRG neurones, the AEA effects on TRPV1 were found to 
inhibit VACC and enhance Ca2+ influx. These effects were best achieved via intracellular delivery of 
AEA rather than its extracellular application [42]. Anandamide-induced intracellular activation of 
TRPV1 receptor leads to increased calcium influx through TRPV1 channels in transfected cells and 
DRG neurones. This might occur prior to activation of cannabinoid receptors and could be related to 
anandamide control over transmitter release [64]. Therefore, influencing the activity of the putative 
AMT might subsequently affect the TRPV1-mediated response of anandamide [65]. 
In rat DRG neurones, TRPV1 channels were activated and/or sensitized by anandamide through 
alteration of protein kinase C (PKC) and protein kinase A (PKA) activities [66-68]. PKC directly 
phosphorylated the amino acid residues in TRPV1 channels resulting in their sensitization and channel 
opening [69]. Along with PKC stimulation, the relief of tonic inhibition of phosphatidyl-inositol-
bisphosphate (PIP2) sensitizes TRPV1 channels. Much evidence suggests roles for inflammatory 
mediators such as nerve growth factor (NGF) and bradykinin in regulating both PKC and PIP2 
signaling [70]. It was found that NGF levels in the medium influence TRPV1 receptor function in 
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cultured DRG neurons. Specifically, high levels of NGF (200 nM compared with 20 nM) increased the 
population of neurones in which AEA activates a current carried through TRPV1 receptors. This 
appears to be specific for this type of signaling since AEA-mediated inhibition of voltage-activated 
Ca2+ channels in DRG neurones was not enhanced by high NGF in the culture medium [71]. 
Natural co-expression of CB1 receptors and TRPV1 receptors was demonstrated in DRG neurones, 
spinal cord, myenteric neurones and rat brain [72-74] with suspected functional cross-talk especially 
for AEA and NADA, the endocannabinoids that activate both receptor types. If these compounds 
originated from outside the cell, they would be predicted to activate CB1 receptors first then TRPV1 
activation occurs after cellular uptake. On the other hand, if these compounds were synthesized inside 
the cell, they would activate TRPV1 channels prior to CB1 receptor activation. In either condition, 
switching between cannabinoid and vanilloid receptor activation occurs upon transport of these 
compounds across the cell membrane. For more details about CB1 and TRPV1 cross talk see 
[71,75,76]. 
4. Hydrolysis 
In 1993, it was first reported that anandamide hydrolysis into free arachidonic acid and 
ethanolamine is catalyzed by FAAH [77]. The brain anandamide levels were found to be 15-fold 
higher due to low anandamide hydrolytic activity in FAAH-knockout mice when compared to the wild 
type animals [78]. FAAH is a membrane-bound protein that is widely distributed in the liver, brain, 
small intestine and many other organs [19,79,80]. Using immunohistochemical localization, it was 
illustrated that FAAH distribution in the brain was heterogeneous, mostly complementary with CB1 
cannabinoid receptor [81] and preferentially located in large neurones such as pyramidal cells in the 
cerebral cortex and hippocampus [82]. The presence of FAAH on the endoplasmic reticulum, away 
from cannabinoid receptors located on the cell membrane, requires the presence of an intracellular 
carrier protein. This carrier overcomes the low solubility of AEA in the hydrophilic cytosol and 
facilitates trafficking from the site of AEA signaling to its primary site of catabolism. Recent studies 
have revealed the contribution of fatty acid binding proteins (FABPs) as intracellular AEA trafficking 
proteins [83].  FAAH could be inhibited either reversibly by trifluoromethyl ketonase (TFMK) [84] or 
irreversibly by phenylmethylsulfonylflouride (PMSF) [85] and URB597 [86] with the resulting 
elevation of the endocannabinoid anandamide. FAAH inhibition, thus, provides a therapeutic 
alternative to direct cannabinoid receptor agonists with added specificity because of the “on demand” 
biosynthesis of anandamide [87]. Novel FAAH inhibitors, PF-750 and PF-622, showed more potent 
and selective inhibition of FAAH in a time-dependent manner [88]. In preclinical studies, URB597 
was found to produce analgesic, anxiolytic-like and antidepressant-like effects in rodents, which are 
not accompanied by overt signs of abuse liability. There is evidence that the drug offers a possible 
therapeutic avenue for the treatment of cannabis withdrawal [89]. Moreover, the effect of dual 
blockage of FAAH and monoacylglycerol lipase (MAGL; the enzyme that hydrolyze 2-AG), by using 
JZL195 was found to mimic the effect of direct CB1 agonists. This contrasts to the outcome of 
selectively blocking either enzyme alone [90]. Recently, FAAH-2 was identified as a second FAAH 
enzyme that hydrolyzes AEA with activity ~30% of that FAAH in intact cells. In contrast to FAAH, 
FAAH-2 was localized on lipid droplets that represent novel sites for AEA and N-aclyethanolamine 
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(NAE) inactivation [91]. It should be noted that FAAH-2 has a limited species distribution and so 
plays no role in investigations of endocannabinoid turnover in mice and rats. Recently, a new isozyme, 
N-acylethanolamine-hydrolyzing acid amidase (NAAA), was detected in several macrophage-like cells 
and showed AEA-degradation activity in acidic pH [92,93].  
Several studies had revealed the activity of the downstream metabolites of AEA. Our studies 
indicated that ethanolamine is active but is modulated by distinct mechanisms, intracellular signaling 
via thapsigargicin and caffeine-sensitive stores and voltage-activated K+ currents in DRG neurons from 
neonatal rats (Figure 3) [94]. As with the actions of AEA on DRG neurons, it is difficult to predict the 
overall action of ethanolamine on neuronal excitability and synaptic transmission. A combination of 
K+ current inhibition and slowed action potential repolarization with enhanced intracellular Ca2+ 
signaling would be predicted to at least initially to enhance neurotransmission. In contrast, sustained 
large increases in voltage-activated K+ currents might be expected to shorten action potentials and 
reduce neuronal excitability. Both of these possible scenarios are consistent with the actions of AEA 
[43] and provide what has previously been described as a capacity for contradictory or reinforcing 
pathways [95]. 
Our data also revealed that ethanolamine enhancement of the intracellular Ca2+ flux was also found 
to be unaffected either in Pertussis toxin (PTX)-treated neurons or with the continual application of 
CB1 antagonist, SR141716 which adds weight to the hypothesis that these effects are not mediated 
through the CB1 receptor signaling pathway involving the inhibitory G-proteins. Moreover, 
ethanolamine modulation of voltage-activated K+ currents was found to occur independently from 
enhancing intracellular Ca2+ levels. The evidence for this was the persistence of modulations of 
voltage-activated K+ currents, firstly, in Ca2+ free media and secondly, in the continual presence of 
thapsigargicin. In line with our findings, it was previously found that AEA-inhibitory actions on 
voltage-activated K+ current occurred independently from the inhibition of VACC [42, 43]. Similarly, 
we found that ethanolamine had no effect on the voltage-activated calcium current but modulated the 
voltage-activated K+ current. These findings enforce the possibility that while modulating effects of 
ethanolamine on voltage-activated K+ current could be mediated through the same anandamide 
signaling pathway, the increased intracellular Ca2+ effects are mediated via intracellular signaling 
mechanism modulating the calcium store. These findings are in agreement with the previous study [43] 
that pointed out the potential role of active, downstream metabolites of anandamide. It was found that 
irreversible blocking of FAAH by phenylmethanesulfonyl fluoride (PMSF), thus preventing the 
hydrolysis of AEA to its downstream metabolites, attenuated the actions of AEA on potassium 
conductance. This finding was supported by the inactivity of hydrolysis-resistant methanandamide in 
modulating potassium current.  
With regard to the other downstream metabolites of AEA, arachidonic acid (AA) is found 
primarily in an esterified form with the membrane phospholipids and is released by the actions of 
phospholipases. Arachidonic acid can be metabolized by three enzymatic pathways: the lipoxygenase 
pathway forming leukotrienes and lipoxins, the cyclooxygenase pathway (COX) producing 
prostaglandins and thromboxanes, and the cytochrome P450 (cP450) pathway generating 
epoxygenated products [96]. Aspirin and other non-steroidal anti-inflammatory drugs (NSAIDs) act 
through inhibiting AA oxidation by COX enzymes thus inhibiting he formation of downstream 
metabolites of AA. Prostaglandin E2 has been shown to increase the sensitivity to noxious stimuli via 
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increasing the excitability of sensory neurones [97]. Additionally, it was found that some endogenous 
cytochrome P450 arachidonic acid metabolites activate cannabinoid receptors CB1 and CB2 in brain, 
kidney and spleen with high affinity and elicited biological response in vivo and in vitro in cultured 
cells expressing CB receptors although AA by itself failed to activate either CB1 or CB2 receptors [98]. 
Figure 3. Schematic diagram showing the possible mechanisms of ethanolamine actions; 
our data suggested that enhancement of the intracellular Ca2+ level produced by 
ethanolamine is mediated through intracellular signalling mechanism influencing the 
thapsigargicin and caffeine-sensitive stores. Ethanolamine modulation of the potassium 
conductance is mediated independently from increased intracellular calcium. 
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5. Oxidation 
In 1997 the oxidative pathway of anandamide mediated via cyclooxygenase-2 (COX-2) was 
identified [99]. This pathway generated prostaglandin E2-ethanolamide (PGE2-EA) which is resistant 
to hydrolysis and does not appear to activate prostanoid receptors, or interact with FAAH or activate 
TRPV1 receptors [100]. These findings made the COX-2 metabolism of AEA unclear in terms of 
biological significance. To date, AEA oxidation metabolites have not been detected in native tissue, 
yet growing evidence has referred to the enhanced role of the oxidative metabolic pathways when the 
endocannabinoid system is activated while FAAH activity is suppressed [101]. Oxidation of AEA can 
be also mediated via lipooxygenase (LOX) enzyme producing 12- and 15-HpETE-EA both in vitro and 
in vivo [102, 103]. These metabolites are still active at the cannabinoid receptors, although less 
effective than the parent compound (AEA), adding another question about the biological relevance of 
such reactions. In FAAH inactivated animals an alternative pathway of AEA catabolism was identified 
through detecting the presence of O-phosphorylcholine-NAE in the CNS tissue. The O-
phosphorlycholine-NAE could be hydrolysed back to its parent compound AEA allowing a 
biochemical route for storing and release of AEA and its congeners rather than being a secondary 
pathway for AEA inactivation [104, 105]. 
6. Concluding Remarks 
While it is well established that the anandamide signaling is tightly controlled by the inactivation 
processes including re-uptake and degradation via either hydrolysis or oxidation, the efficacy of such 
processes in terminating AEA actions is still a matter of debate. Anandamide re-uptake could be 
viewed as a switching mechanism from one receptor, CB1, to another, TRPV1. While the metabolites 
of anandamide degradation showed various intracellular activities which could either potentiate or 
counteract anandamide actions. Thus, it is important to characterize the predominant factor that could 
be varied from one cell to another according to the distribution of endocannabinoid-targeted receptors 
and degradation enzymes. Proper characterization of tissue-specific inactivation could direct 
endocannabinoid-therapeutic strategies to more specific actions and minimize the side effects. 
Moreover, future studies may consider other ways of terminating AEA actions such as down regulation 
and/or desensitization of the endocannabinoid-targeted receptors. 
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